BACKGROUND: Understanding the prevalence of potential antigenic variation of the hepatitis B virus (HBV) surface antigen (HBsAg) is fundamental for assay design and to future changes in vaccine formulation. In this study, the nature and frequency of HBsAg polymorphisms occurring in France in chronic carriers and in newly diagnosed patients were determined. We focused on variations in the major hydrophilic region (MHR), the central core of HBsAg known to be exposed on the surface and involved in antibody binding. METHODS: Two patient groups were identified: 51 chronic HBV carriers followed at our institution for > 1 year; and 129 newly diagnosed patients (63 of whom had a first HBsAg-positive result at our hospital laboratory and 66 a first positive result in a private laboratory). DNA sequences of HBsAg were obtained from these 180 patients and compared with consensus sequences built with 168 full-length HBV sequences imported from GenBank. Polymorphisms of the MHR of HBsAg were analysed with the Mutation Master Software. Literature review and BLOSUM scores were used to define potentially altered antigenicity. RESULTS: The global frequency of MHR variants was 27.8%. Occurrence of MHR variants was independent of viral load, HBeAg status and sex, but was associated with the chronic carriers' group, advancing age, the presence of antibodies to HBsAg, immunoprophylaxis administration, antiviral treatment and genotypic resistance to antivirals. In multivariate analysis, the independent variables associated with MHR variants were advancing age and the presence of genotypic resistance to nucleoside or nucleotide analogues. CONCLUSION: Most MHR variants emerge with longer disease duration and upon indirect selective pressure. Variation of the MHR may serve to restore virus replication of resistant strains. Combined envelope and polymerase variants could impair diagnostic assays and limit treatment alternatives.
BACKGROUND: Understanding the prevalence of potential antigenic variation of the hepatitis B virus (HBV) surface antigen (HBsAg) is fundamental for assay design and to future changes in vaccine formulation. In this study, the nature and frequency of HBsAg polymorphisms occurring in France in chronic carriers and in newly diagnosed patients were determined. We focused on variations in the major hydrophilic region (MHR), the central core of HBsAg known to be exposed on the surface and involved in antibody binding. METHODS: Two patient groups were identified: 51 chronic HBV carriers followed at our institution for > 1 year; and 129 newly diagnosed patients (63 of whom had a first HBsAg-positive result at our hospital laboratory and 66 a first positive result in a private laboratory). DNA sequences of HBsAg were obtained from these 180 patients and compared with consensus sequences built with 168 full-length HBV sequences imported from GenBank. Polymorphisms of the MHR of HBsAg were analysed with the Mutation Master Software. Literature review and BLOSUM scores were used to define potentially altered antigenicity. RESULTS: The global frequency of MHR variants was 27.8%. Occurrence of MHR variants was independent of viral load, HBeAg status and sex, but was associated with the chronic carriers' group, advancing age, the presence of antibodies to HBsAg, immunoprophylaxis administration, antiviral treatment and genotypic resistance to antivirals. In multivariate analysis, the independent variables associated with MHR variants were advancing age and the presence of genotypic resistance to nucleoside or nucleotide analogues. CONCLUSION: Most MHR variants emerge with longer disease duration and upon indirect selective pressure. Variation of the MHR may serve to restore virus replication of resistant strains. Combined envelope and polymerase variants could impair diagnostic assays and limit treatment alternatives.
Authors: Richard F Jones; Joyce D Reyes; Heather M Gibson; Jennifer B Jacob; Ulka Vaishampayan; Stuart Ratner; Kang Chen; Wei-Zen Wei Journal: Cancer Immunol Immunother Date: 2019-06-08 Impact factor: 6.968
Authors: X Y Wang; T J Harrison; X He; Q Y Chen; G J Li; M H Liu; H Li; J Y Yang; Z L Fang Journal: Epidemiol Infect Date: 2015-04-23 Impact factor: 4.434
Authors: Haimanti Bhattacharya; Debdutta Bhattacharya; S R Ghosal; Subarna Roy; A P Sugunan Journal: Indian J Med Res Date: 2015-05 Impact factor: 2.375
Authors: Licel A Rodríguez Lay; Marité B Corredor; Maria C Villalba; Susel S Frómeta; Meilin S Wong; Lidunka Valdes; Marcia Samada; Aurélie Sausy; Judith M Hübschen; Claude P Muller Journal: PLoS One Date: 2015-05-15 Impact factor: 3.240
Authors: Dahlene N Fusco; Lilia Ganova-Raeva; Yury Khudyakov; Lili Punkova; Aisha Mohamed; Scarlett Se Yun Cheon; Prapti Koirala; Karin L Andersson; Gonzague Jourdain; Camille Sureau; Raymond T Chung; Georg Lauer Journal: Front Med (Lausanne) Date: 2018-04-30